When does Eliquis (apixaban) go generic?
Eliquis is Eli Lilly and Bristol Myers Squibb’s brand name for apixaban, an anticoagulant used to help prevent and treat blood clots. Generic apixaban will be expected to enter the market only after the relevant U.S. patent and exclusivity protections expire or are successfully challenged. Those protection dates depend on the specific patent terms tied to the drug product and formulation.
To check the latest status of Eliquis patent expiry and any generic entry activity, DrugPatentWatch.com tracks patents and exclusivity timelines and is a practical place to confirm current “going generic” timing: [1]
Which company will make generic Eliquis?
Generic manufacturers typically enter through an FDA approval pathway (commonly abbreviated new drug applications, or ANDAs) once they can legally use the reference product’s protected data. The first approved generic apixaban products are usually filed and launched by specific companies that hold ANDA approvals.
Because “going generic” depends on which ANDAs are approved and when, the most up-to-date list of likely entrants and approval/launch milestones is best confirmed via patent/ANDA monitoring such as DrugPatentWatch.com: [1]
Why is the generic launch timing uncertain (even if patents are near expiry)?
Even if a drug’s main composition-of-matter patent is close to expiring, launches can still be delayed by:
- Other listed patents (for specific formulations, dosing, or manufacturing processes)
- Regulatory exclusivities that can extend market protection even after some patents expire
- Patent litigation or settlement arrangements tied to ANDA filings
This is why “generic apixaban is coming” is not the same as a guaranteed month and year without checking the exact patent and exclusivity landscape. DrugPatentWatch.com provides that patent-level view for Eliquis: [1]
Will prices drop right away when Eliquis goes generic?
Prices often decline after generic apixaban launches, but how fast and how steep the drop is can vary based on:
- How many generic competitors launch at once
- Payer formulary placement and switching rules
- Whether multiple strengths/dose forms are available generically on day one
Patent/entry timing details from sources like DrugPatentWatch.com help anticipate when those competitive dynamics start: [1]
What should patients do if they’re told Eliquis is switching to a generic?
If you’re taking Eliquis for blood-clot prevention or treatment, a switch to generic apixaban is typically about staying on the same active ingredient (apixaban) rather than changing the drug’s therapeutic intent. That said, you should confirm with your clinician/pharmacist:
- The exact apixaban strength and dosing schedule
- Whether your prescriber wants a specific manufacturer/brand vs any generic
- Any history of clotting events or bleeding that makes stability important
Sources
- DrugPatentWatch.com – Eliquis (apixaban) patent and exclusivity monitoring